ISRIB Modulation of p-eIF2α Pathway for Skeletal Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skeletal disorders associated with the integrated stress response (ISR) and ER stress, such as Metaphyseal chondrodysplasia, type Schmid (MCDS), are ineffective, and there is a lack of understanding on how cells adapt and differentiate under chronic stress, hindering the development of effective pharmacological therapies.
Innovation Solution
The method involves targeting the p-eIF2α pathway using a small molecule inhibitor, ISRIB, which suppresses ATF4 induction, thereby preventing aberrant cell differentiation and alleviating skeletal deformities by modulating the ISR pathway, and using p-eIF2α modulators to treat conditions like MCDS and intervertebral disc degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current surgical treatments are used for skeletal disorders, then skeletal deformities can be corrected, but the treatment complexity and patient risk increase significantly
Solution Approach 1:
The patent replaces mechanical surgical interventions with a pharmacological approach using small molecule inhibitors that target the p-eIF2α pathway. Instead of physically correcting skeletal deformities through surgery, the invention uses molecular compounds to modulate cellular stress responses and prevent aberrant cell differentiation, thereby treating the underlying cause rather than correcting the mechanical outcome.
2Reliability
If ER stress is reduced in mutant ECM protein models, then cell survival improves, but aberrant cell differentiation is promoted
Solution Approach 1:
The patent changes the parameter being targeted from ER stress levels to downstream signaling in the p-eIF2α pathway. By using small molecule inhibitors that specifically modulate ATF4 induction and CHOP expression rather than directly reducing ER stress, the invention alters the cellular response parameters to achieve both cell survival and prevention of aberrant differentiation simultaneously.
3Stability of the object's composition
If the p-eIF2α pathway is inhibited to prevent aberrant differentiation, then skeletal deformities are reduced, but cell survival under stress may be compromised
Solution Approach 1:
The patent applies partial inhibition of the p-eIF2α pathway rather than complete blockade. The small molecule inhibitors are designed to selectively suppress ATF4 induction and downstream CHOP expression while allowing other essential stress response functions to continue. This partial action achieves sufficient prevention of aberrant differentiation without completely compromising cell survival mechanisms.
Data Source
AI summary
The present invention describes a method of preventing, ameliorating and/or treating disorders or diseases associated with the integrated stress response (ISR) involving the p-eIF2α pathway arising from various cellular stresses such as oxidative stress, hypoxia and ER stress, chronic or prolonged bio-mechanical stress. In one embodiment, the present invention provides a method which prevents or alleviates aberrant cell differentiation that is caused by the activation of the integrated stress response and thereby prevents or alleviates conditions, disorders or diseases resulting therefrom. In one embodiment, ISR-associated diseases subject to the present invention include but are not limited to skeletal disorders including disc degeneration, MCDS and other skeletal dysplasias, cancers, inflammatory diseases, diabetes, fibrosis, obesity and neurodegenerative diseases. In another embodiment, the present invention provides a method of using a p-eIF2α-modulator for the prevention or treatment of conditions, disorders or diseases described herein.